Breast Cancer Clinical Trial
— ALERTOfficial title:
ALERT: A Phase II Study of Alternating Eribulin and Hormonal Therapy in Pre-treated ER+ve Breast Cancer.
Verified date | January 2021 |
Source | Imperial College London |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
A single centre, single arm phase II study of alternating eribulin and hormonal therapy in 12 patients with locally advanced or metastatic breast cancer who have received at least one hormonal therapy and at least one chemotherapy in the metastatic setting.
Status | Terminated |
Enrollment | 8 |
Est. completion date | July 24, 2018 |
Est. primary completion date | July 24, 2018 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - 1. Written informed consent prior to admission to this study - 2. Aged 18=over - 3. Histologically confirmed ER+ve metastatic breast cancer according to local criteria - 4. Eastern Cooperative Oncology Group (ECOG) performance status 0 - 2 - 5. Have progressed after at least one hormonal therapy regime and at least one chemotherapy regime for advanced disease - 6. Patients must have had prior treatment with an anthracycline and a taxane (either sequential or in combination) unless patients were not suitable for these treatments. This treatment can be in the adjuvant setting - 7. Measurable sites of locally advanced and/or metastatic disease that can be accurately assessed by CT/MRI scan at baseline (RECIST v1.1)¹ - 8. Life expectancy of =6 months - 9. Adequate organ function, as defined by: - Haemoglobin (Hb) = 9 g/dL - Absolute Neutrophil Count (ANC) = 1.5 x 109/L - Platelet count (Plts) = 100 x 109/L - White Blood Cell (WBC) = 3.0 x 109/L - Serum albumin = 1.5 Upper Limit of Normal (ULN) - Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) = 3 x ULN if no demonstrable liver metastases or = 5 x ULN in the presence of liver metastases. - Alkaline Phosphatase Level (ALP) = 5 x ULN - Total bilirubin = 1.5 x ULN if no demonstrable liver metastases or = 3 x ULN in the presence of liver metastases - Creatinine = 1.5 x ULN or creatinine clearance >50ml/min - 10. Postmenopausal as defined by age >50, no menstruation for >2 years, previous oophorectomy or lab results confirming this status - 11. Premenopausal if has been subject to ovarian ablation/ suppression at least 3 weeks prior to commencing AI therapy - RECIST v1.1 updated and now considers bone metastasis with an identifiable soft tissue mass to be measurable disease. Therefore, patients with bone metastasis are eligible, provided they have evaluable disease. Exclusion Criteria: - 1.Triple negative or Human Epidermal Growth Factor Receptor 2 (HER2) positive cancer - 2. Hypersensitivity to the active substance or to any of its excipients - 3. History of another primary malignancy within 5 years prior to starting study treatment, except adequately treated basal or squamous cell carcinoma of the skin, carcinoma in site and the disease under study - 4. Evidence of uncontrolled active infection - 5. Severe hepatic impairment (Child-Pugh C) - 6. Evidence of significant medical condition or laboratory finding which, in the opinion of the Investigator, makes it undesirable for the patient to participate in the trial - 7. Concurrent therapy with any other investigational agent or everolimus - 8. Concomitant use within 14 days prior to commencement of study treatment of any investigational agent - 9. Uncontrolled abnormalities of serum potassium, sodium, calcium (corrected) phosphate or magnesium levels - 10. Pregnant or lactating women. Effective non-hormonal contraception is mandatory for all patients of reproductive potential - 11. Evidence of ovarian activity - 12. Prior eribulin therapy |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Charing Cross Hopsital | London |
Lead Sponsor | Collaborator |
---|---|
Imperial College London |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Estimated Kaplan-Meier Progression Free Survival as Assessed by RECIST v1.1 | Estimated Kaplan-Meier Progression free survival (PFS) to be defined as time from study entry to first evidence of disease progression or death due to any cause, as assessed by RECIST v1.0. | Fixed timepoints - 3, 6 and 9 months | |
Secondary | Clinical Benefit Rate as Assessed by RECIST v1.1 | Clinical benefit rate (CBR), defined as the proportion of patients whose best overall response according to Response Evaluation Criteria in Solid Tumours (RECIST), v1.0 is either a complete response, partial response or stable disease for a least 6 months. | To be assessed at 3, 6 and 9 months. | |
Secondary | Safety and Tolerability | Safety and Tolerability were assessed by adverse events (AEs) and serious adverse events (SAEs) according the Common Terminology Criteria for Adverse Event (NCI-CTCAE) v4.03. | Collected form consent to follow-up |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Recruiting |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Recruiting |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 |